335

Indus

try s

pons

ored

symp

osIa

F i n a l P r o g r a m m e

Industry Sponsored Symposia

INDUSTRY SPONSORED SYMPOSIA

pageSunday, May 22, 2016 13:30-15:00Hall D Fresenius Medical Care 336Hall E Vifor Fresenius Medical Care Renal Pharma 337Hall B B.Braun 338Hall C Baxter Healthcare 339Hall G Alexion Pharma International 340Hall K Chiesi Farmaceutici 341Lounge 3 Shire International 342Hall N Immunodiagnostic Systems & Natto Pharma 343

18:45-19:45Hall G Merck Sharp & Dohme 344Hall K Amgen 345Hall N Bayer 346

Monday, May 23, 2016 13:30-15:00Hall D Baxter Healthcare 347Hall E Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance 348Hall F Otsuka Pharmaceutical Europe 349Hall B Vifor Fresenius Medical Care Renal Pharma 350Hall C Astra Zeneca 351Hall G Sanofi Genzyme 352Hall K Novartis Pharma 353Hall M NxStage Medical 354Hall N Raptor Pharmaceuticals 355

Tuesday, May 24, 2016 12:15-13:15Hall K Sigma-Tau 356

336

Held jointly with

w w w . e r a - e d t a 2 0 1 6 . o r g

Industry Sponsored SymposiaInd

ustr

y spo

nsor

ed sy

mpos

Ia

Sunday, May 22, 2016 13:30-15:00Hall D

Improving Outcomes of Advanced Chronic Kidney Disease Patients by "Personalized and Precise Renal Replacement Therapy"

Chairs: Andrew Davenport, London, United Kingdom Mariano J. Rodríguez Portillo, Cordoba, Spain

Cardiovascular Protection: How to balance benefit/risk by fluid and electrolytes managementDaniel Schneditz, Graz, Austria

Improving Intradialytic Stability: How to reduce the risk of extracorporeal thrombotic eventsMartin Kuhlmann, Berlin, Germany

Uremic Toxicity, Gut-Kidney Axis and Renal Replacement Therapy: How to improve outco-me of advanced CKD patients by a multi-targeted approachGriet Glorieux, Ghent, Belgium

Organised by FRESENIUS MEDICAL CARE

337

Indus

try s

pons

ored

symp

osIa

F i n a l P r o g r a m m e

Industry Sponsored Symposia

Sunday, May 22, 2016 13:30-15:00Hall E

Protecting heart, vessels and bone - new ways to control phosphorus and potassium

Chairs: Markus Ketteler, Coburg, Germany Alexander Rosenkranz, Graz, Austria

Hyperphosphatemia - understanding the challengesLaurent Juillard, Lyon, France

Advances in the management of hyperphosphatemiaPhilip Kalra, Manchester, United Kingdom

A new approach in potassium management - can we change the treatment paradigm?Matthew R. Weir, Baltimore, U.S.A.

Organised by VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA

338

Held jointly with

w w w . e r a - e d t a 2 0 1 6 . o r g

Industry Sponsored SymposiaInd

ustr

y spo

nsor

ed sy

mpos

Ia

Sunday, May 22, 2016 13:30-15:00Hall B

Optimal Treatment Targets in Renal Replacement Therapy - How to achieve them?

Chair: Joachim Hoyer, Marburg, Germany

Tailor-made hemodialysate composition - effects on hemodynamic stabilityFrancesco Locatelli, Lecco, Italy

Convection volume in HDF - lessons learned for daily practicePeter J. Blankestijn, Utrecht, The Netherlands

Renal dose achievement in AKI - influential factorsAntoine Schneider, Lausanne, Switzerland

Organised by B.BRAUN

339

Indus

try s

pons

ored

symp

osIa

F i n a l P r o g r a m m e

Industry Sponsored Symposia

Sunday, May 22, 2016 13:30-15:00Hall C

Uremic toxins: urea, β2-microglobulin and beyond

Chair: Peter Stenvinkel, Stockholm, Sweden

From low-flux HD to high-flux and HDF: what's next? Muriel Grooteman, Amsterdam, The Netherlands

Uremic toxins beyond β2m: what role do they play?Colin Hutchison, Hawke's Bay, New Zealand

Albumin removal by dialysis: is there reason to be concerned?Peter Stenvinkel, Stockholm, Sweden

Organised by BAXTER HEALTHCARE

340

Held jointly with

w w w . e r a - e d t a 2 0 1 6 . o r g

Industry Sponsored SymposiaInd

ustr

y spo

nsor

ed sy

mpos

Ia

Sunday, May 22, 2016 13:30-15:00Hall G

TMA: multiple causes for a disease with 100 faces?

Chair: Manuel Praga, Madrid, Spain

Recognising the many faces of TMAManuel Praga, Madrid, Spain

Facing the future: rapid differential diagnosis of TMAChristian Haas, Lübeck, Germany

The changing face of TMA diagnosis for the kidney transplant patientJulien Zuber, Paris, France

Organised by ALEXION PHARMA INTERNATIONAL

341

Indus

try s

pons

ored

symp

osIa

F i n a l P r o g r a m m e

Industry Sponsored Symposia

Sunday, May 22, 2016 13:30-15:00Hall K

Advancements in immunosuppression: are all tacrolimus formulations the same?

Chair: Rainer Oberbauer, Vienna, Austria

Control and optimization: the answer in PKPierre Marquet, Limoges, France

Management and clinical outcomes: the answer of the clinicianJulio Pascual, Barcelona, Spain

Organised by CHIESI FARMACEUTICI

342

Held jointly with

w w w . e r a - e d t a 2 0 1 6 . o r g

Industry Sponsored SymposiaInd

ustr

y spo

nsor

ed sy

mpos

Ia

Sunday, May 22, 2016 13:30-15:00Lounge 3

Rare diseases and the kidney: unexplained story and complexity of Fabry disease

Chairs: Gere Sunder-Plassmann, Vienna, Austria Olivier Devuyst, Zurich, Switzerland

Welcome and IntroductionGere Sunder-Plassmann, Vienna, Austria

Overview and Common Misdiagnosis of Rare Diseases in NephrologyOlivier Devuyst, Zurich, Switzerland

Pathophysiology and Treatment of Fabry Disease: It’s Not as Simple as we May ThinkSandro Feriozzi, Viterbo, Italy

How to Identify Fabry Disease Among Renal Patients: The Importance of ScreeningPablo Neumann, Buenos Aires, Argentina

Organised by SHIRE INTERNATIONAL

343

Indus

try s

pons

ored

symp

osIa

F i n a l P r o g r a m m e

Industry Sponsored Symposia

Sunday, May 22, 2016 13:30-15:00Hall N

The infernal triad: matrix-gla-protein, vitamin K and vascular calcification

Chairs: Jürgen Floege, Aachen, Germany Etienne Cavalier, Liege, Belgium

Vascular calcification in CKD patientsZiad Massy, Paris, France

Vitamin K-dependent matrix Gla-protein: a crucial switch to control ectopic mineralizationLeon Schurgers, Maastricht, The Netherlands

Vitamin K2: an essential nutrient for cardiovascular healthKatarzyna Maresz, Krakow, Poland

Organised by IMMUNODIAGNOSTIC SYSTEMS & NATTO PHARMA

344

Held jointly with

w w w . e r a - e d t a 2 0 1 6 . o r g

Industry Sponsored SymposiaInd

ustr

y spo

nsor

ed sy

mpos

Ia

Sunday, May 22, 2016 18:45-19:45Hall G

Treatment of Hepatitis C in Patients with Chronic Kidney Disease: Challenges and Opportunities

Chair: Marcus Säemann, Vienna, Austria

The Burden of Hepatitis C in Patients with Chronic Kidney DiseaseAnnette Bruchfeld, Stockholm, Sweden

Therapeutic Options and Guidelines for the Treatment of Hepatitis C in Patients with Chronic Kidney DiseaseDavid Roth, Miami, U.S.A.

Organised by MERCK SHARP & DOHME

345

Indus

try s

pons

ored

symp

osIa

F i n a l P r o g r a m m e

Industry Sponsored Symposia

Sunday, May 22, 2016 18:45-19:45Hall K

Treating secondary hyperparathyroidism with calcimimetics; new insights

Chair: David Wheeler, London, United Kingdom

Lessons learnt from the EVOLVE studyJürgen Floege, Aachen, Germany

Etelcalcetide - a new injectable calcimimetic for the treatment of secondary hyperparathyroidismMarkus Ketteler, Coburg, Germany

Organised by AMGEN

346

Held jointly with

w w w . e r a - e d t a 2 0 1 6 . o r g

Industry Sponsored SymposiaInd

ustr

y spo

nsor

ed sy

mpos

Ia

Sunday, May 22, 2016 18:45-19:45Hall N

DKD: getting to the heart of the matter

Chair: Hermann Haller, Hannover, Germany

Cardiovascular outcomes in patients with diabetic kidney disease: epidemiology and patho-physiologyPatrick Rossignol, Nancy, France

Emerging therapies for reducing renal and cardiovascular risk in patients with diabetic kidney diseasePeter Rossing, Gentofte, Denmark

Organised by BAYER

347

Indus

try s

pons

ored

symp

osIa

F i n a l P r o g r a m m e

Industry Sponsored Symposia

Monday, May 23, 2016 13:30-15:00Hall D

Optimizing the ESRD patient journey and RRT clinical-economic outcomes

Chair: Simon Davies, Stoke-on-Trent, United Kingdom

Challenging the deadly paradigm of RRT modality transitions: an integrated approach to the patient ESRD journey Wim Van Biesen, Ghent, Belgium

Doing the right thing at the right time: shared decision-making with RRT modality selection Eero Honkanen, Helsinki, Finland

The role of RPM and telemedicine in optimizing RRT modality outcomes and facilitating healthy transitions Claus Peter Schmitt, Heidelberg, Germany

Organised by BAXTER HEALTHCARE

348

Held jointly with

w w w . e r a - e d t a 2 0 1 6 . o r g

Industry Sponsored SymposiaInd

ustr

y spo

nsor

ed sy

mpos

Ia

Monday, May 23, 2016 13:30-15:00Hall E

SGLT2 inhibition: Is this a novel approach to prevent the progression of diabetic kidney disease?

Chair: Gert Mayer, Innsbruck, Austria

Current challenges when treating patients with Type 2 Diabetes & Kidney DiseaseVlado Perkovic, Sydney, Australia

New evidence at the interface of Type 2 Diabetes & Kidney Disease: The EMPA-REG OUTCOME® TrialChristoph Wanner, Würzburg, Germany

SGLT2 inhibition: How does it work in the kidney?David Cherney, Toronto, Canada

Implications for clinical practiceVlado Perkovic, Sydney, Australia

Organised by BOEHRINGER INGELHEIM & ELI LILLY AND COMPANY DIABETES ALLIANCE

349

Indus

try s

pons

ored

symp

osIa

F i n a l P r o g r a m m e

Industry Sponsored Symposia

Monday, May 23, 2016 13:30-15:00Hall F

ADPKD Treatment Update

Chair: Roser Torra, Barcelona, Spain

Welcome and introductionRoser Torra, Barcelona, Spain

Updated results of TEMPO 3:4Vicente Torres, Rochester, U.S.A.

How to identify patients with rapidly progressing ADPKDHenrik Birn, Aarhus, Denmark

Initiation and maintenance of tolvaptan: From theory into practice and early insight from the clinicRoman-Ulrich Müller, Cologne, Germany

Panel discussionRoser Torra, Barcelona, Spain

Closing remarksRoser Torra, Barcelona, Spain

Organised by OTSUKA PHARMACEUTICAL EUROPE

350

Held jointly with

w w w . e r a - e d t a 2 0 1 6 . o r g

Industry Sponsored SymposiaInd

ustr

y spo

nsor

ed sy

mpos

Ia

Monday, May 23, 2016 13:30-15:00Hall B

New insights into iron metabolism and deficiency

Chairs: Angel Luis Martin de Francisco, Santander, Spain Kai-Uwe Eckardt, Erlangen, Germany

ID prevalence in patients with CKD - a matter of definition?Kai-Uwe Eckardt, Erlangen, Germany

Iron pathophysiology - its complexity and our knowledge gapsTomas Ganz, Los Angeles, U.S.A.

Diagnosing and treating ID/IDA - meeting your patient's needsJolanta Malyszko, Bialystok, Poland

Organised by VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA

351

Indus

try s

pons

ored

symp

osIa

F i n a l P r o g r a m m e

Industry Sponsored Symposia

Monday, May 23, 2016 13:30-15:00Hall C

Management of Hyperkalemia: Challenges and Considerations in Patients with CKD

Chair: David Goldsmith, London, United Kingdom

Pathophysiology and Risk of HyperkalemiaJohannes F.E. Mann, Munich, Germany

Current and Emerging Options for Outpatient Treatment of HyperkalemiaMartin H. de Borst, Groningen, The Netherlands

Supported by an educational grant from ASTRA ZENECA

352

Held jointly with

w w w . e r a - e d t a 2 0 1 6 . o r g

Industry Sponsored SymposiaInd

ustr

y spo

nsor

ed sy

mpos

Ia

Monday, May 23, 2016 13:30-15:00Hall G

Unknown unknowns in Chronic Kidney Disease

Chair: Alberto Ortiz, Madrid, Spain

What is an unknown unknown in Chronic Kidney Disease? Prevalence of undiagnosed primary and secondary causes of CKDGiuseppe Castellano, Bari, Italy

Utility of renal biopsies in diagnosis and treatment of secondary and rare causes of CKDAlberto Ortiz, Madrid, Spain

KDIGO Conference on Fabry Nephropathy: Management of rare causes of Chronic Kidney DiseaseBojan Vujkovac, Slovenj Gradec, Slovenia

Organised by SANOFI GENZYME

353

Indus

try s

pons

ored

symp

osIa

F i n a l P r o g r a m m e

Industry Sponsored Symposia

Monday, May 23, 2016 13:30-15:00Hall K

Working to Preserve Renal Function in Patients with Tuberous Sclerosis Complex

Chair: J. Chris Kingswood, Brighton, United Kingdom

Natural course of renal function in patients with TSC Bernard Zonnenberg, Utrecht, The Netherlands

Current monitoring guidelines and treatment options for TSC-related renal manifestationsKlemens Budde, Berlin, Germany

Safety and efficacy of mTOR inhibitors J. Chris Kingswood, Brighton, United Kingdom

Organised by NOVARTIS PHARMA

354

Held jointly with

w w w . e r a - e d t a 2 0 1 6 . o r g

Industry Sponsored SymposiaInd

ustr

y spo

nsor

ed sy

mpos

Ia

Monday, May 23, 2016 13:30-15:00Hall M

Challenges to improve hemodialysis outcomes: are "frequent" and "home" the answers?

Chairs: Eric Goffin, Bruxelles, Belgium Maxence Ficheux, Caen, France

Home HD: How it looks and how it worksShashidhar Cherukuri, Wolverhampton, United Kingdom

The ‘suitable’ patient and prescribing home HDNatalie Borman, Portsmouth, United Kingdom

The European experience: Clinical outcome from the KIHDNEy cohortPer Westerlund, Kristianstad, Sweden

Patient experience: what are the success factorsHafedh Fessi, Paris, France

Organised by NXSTAGE MEDICAL

355

Indus

try s

pons

ored

symp

osIa

F i n a l P r o g r a m m e

Industry Sponsored Symposia

Monday, May 23, 2016 13:30-15:00Hall N

Rare Renal Diseases Are Growing Up

Chair: Rainer Oberbauer, Vienna, Austria

Cystinosis vs CKD: Growth and neurocognitive development in childhoodDieter Haffner, Hannover, Germany

Managing the Adolescent PatientGraham Lipkin, Birmingham, United KingdomLarissa Kerecuk, Birmingham, United Kingdom

Cystinosis in Adults; An Emerging PopulationAlbane Brodin-Sartorius, Paris, France

Organised by RAPTOR PHARMACEUTICALS

356

Held jointly with

w w w . e r a - e d t a 2 0 1 6 . o r g

Industry Sponsored SymposiaInd

ustr

y spo

nsor

ed sy

mpos

Ia

Tuesday, May 24, 2016 12:15-13:15Hall K

Secondary Carnitine Deficiency in Dialysis Patients-Shall We Supplement it?

Chairs: Ronald Wanders, Amsterdam, The Netherlands Tim Ulinski, Paris, France

Carnitine in Human Health and Disease Including Genetic Metabolic DisordersRonald J.A.Wanders, Amsterdam, The Netherlands

Characteristics of Dialysis-Related Carnitine Deficiency - Effectiveness of L-carnitine for the Treatment of Erythropoietin-Resistant Renal AnaemiaStephanie Reuter Lange, Adelaide, Australia

Carnitine Levels, Myocardial Function and Survival Outcomes in Children Receiving Chronic Hemodialysis and Continuous Renal Replacement TherapyAsha Moudgil, Washington, U.S.A.

Organised by SIGMA-TAU